Meeting
2016 ASCO Annual Meeting
Population-based assessment of disease free survival (DFS) as a surrogate endpoint (SE) of 5 year overall survival (5Y OS) in stage I-III rectal (RC) and colon cancer (CC).
Authors
Richard M. Lee-Ying
University of Calgary Tom Baker Cancer Centre, Calgary, AB, Canada
Richard M. Lee-Ying , Yaling Yin , Howard John Lim , Winson Y. Cheung , Hagen F. Kennecke
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Epidemiology/Outcomes
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3602)
DOI
10.1200/JCO.2016.34.15_suppl.3602
Abstract #
3602
Poster Bd #
299
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Disease-free survival (DFS) as a surrogate for overall survival (OS) in patients (pts) with HR+/HER2− early breast cancer (EBC): A correlation analysis.
First Author: Michael Untch
Poster
2023 ASCO Annual Meeting
The value of progression-free survival at three years as a primary endpoint for studies on radiotherapy in patients with locally advanced cervical cancer: Individual patient data from Chinese National Cancer Center and validation from 27 global randomized trials.
First Author: Xi Yang
Poster
2021 ASCO Annual Meeting
Prognostic value of baseline and early changes of circulating-free (cf) and circulating tumor (ct) DNA in the neoadjuvant (NA) setting of early stage colon cancer (CC).
First Author: Giacomo Bregni
Poster
2020 ASCO Virtual Scientific Program
Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of phase II study.
First Author: Christine H. Chung